2013, Number 2
PDF size: 133.00 Kb.
ABSTRACTThe search for new therapeutic options to treat bronchial obstructive diseases represents a permanent challenge and bronchodilators constitute one of the most used drugs in the treatment of these patients. In recent years, long acting bronchodilators have grown importance, but the greatest effect has been 12 h, superseded by a new bronchodilator that came on to the market in the year 2011 named Indacaterol, which belongs to the group of ß2-agonists and differentiates from the rest for its effect on the duration which lasts 24 hours. A randomized, essay-type, blind, prospective study was performed in 90 asthmatic patients, ranging from 18 to 59 years of age that presented to the department of respiratory functional tests for a study of their pulmonary functions. All the patients randomly received Indacaterol, Salbutamol or Placebo and spirometry was repeated 15 minutes and 24 hours after treatment. It was evidenced that the bronchodilator response obtained at the 24 hours in those patients that used Indacaterol, was higher than the response in the patients that used other drugs. The patients that used Indacterol and Salbutamol also showed a discrete increase of the cardiac frequency and blood pressure, mainly 15 minutes after receiving such drugs, but this increase is considered within the normal limits. Adverse effects were not evidenced.
National Asthma Education Program NH, Lung and Blood Institute, Expert Panel Report 3. Guidelines for the Diagnosis and Management of Asthma. NHI Publication No. 07-4051;2007.
Fogarty C, Hébert J, Iqbal A. Indacaterol once-daily provides effective 24-h bronchodilation in COPD patients in COPD patients: a 26 week evaluation vs. placebo and tiotropium. Eur Respir J. 2009;34(Suppl 53):2025.
Kramer J. Balancing the benefits and risk of inhaled long acting beta agosnist. The influence of values. N Engl J Med. 2009;1592-3.
Dahl R. Chung KF, Buhl R. Magnussen H, Nonifov V. Efficacy of a new once-daily long-acting inhaled ß2-agonist indacaterol versus twice-daily formoterol in COPD. Thorax. 2010;65:473-9.
Kornmann O, Dahl R, Centanni S, Dogra A. Once-daily indacaterol vs. twice-daily salmeterol for COPD: a placebo-controlled comparison. Eur Respir J. 2010;50:120-30.
Vogelheimer C. Indacaterol provides 24-hour bronchodilatation in COPD: a placebo-controlled blinded comparison with tiotropium. Resp Res. 2010;11:135. doi: 10. 1186/1465-9921-11-135.
Comparison of indacaterol and tiotropium of lung function and related outcomes in patients with chronic obstructive pulmonary disease (COPD) (INVIGORATE). [Citado 5 Nov. 2010.] Disponible en: http://www.ukctg.nihr.ac.uk/trialdetails/NCT00845728
Pearlman D, Greos L, LaForce C. Indacaterol, a novel once-daily ß2-agonist, provides full 24-hour bronchodilatory efficacy in patients with persistent asthma. Presented at the International Conference of the American Thoracic Society, San Diego, Calif., 2009 (Abstract 2950).
Calverley P, Anderson JA, Bartolome Celli BA, Ferguson GT. Salmeterol and Fluticasone Propionate and survival in chronic obstructive pulmonary disease. N Engl J Med. 2007;356:775-89.
Grupo de trabajo de la guía práctica clínica sobre atención integral al paciente con enfermedad pulmonar obstructiva crónica (EPOC). Desde la atención primaria a la especializada. Sociedad Española de Medicina de Familia (semFYC) y Sociedad Española de Neumología y Cirugía Torácica; 2010. p. 120-45.
Balint B. Onset of action of indacaterol in patients with COPD: Comparison with salbutamol and salmeterol-fluticasone. Int J Chron Obstruct Dis. 2010;5:311-8.
Pellegrino R, Viegi G, Brusasco V, Crapo RO. Interpretative strategies for lung function test. Eur Respir J. 2005;26:948-68.
Miller MR, Hankinson J, Brusasco V. Standardisation of spirometry. Eur Respir J. 2005;26:319-38.
Fogarty C, Hebert J, Iqbal A. Indacaterol once-daily provide effective 24-h broncodilatation in COPD patients. Eur Respir J. 2009;34 (Suppl 53):2025.
La Force C. Aumann, on behalf of the INTEGRAL study investigators. Sustained 24-hour efficacy of once daily indacaterol (300 μg) in patients with chronic obstructive pulmonary disease: A randomized, crossover study. Pulm Pharmacol Ther. 7 Jul. 2010 [Epub ahead of print].